COX-2 inhibitor

COX-2 inhibitor has been studied in 5 papers since 2016: 2 observational studies in people, 2 in animals, 1 review. The newest paper, Aug 6, 2025: “Effects of NSAIDs on Early CKD Development: A 10-Year Population-Based Study Using the Korean Senior Cohort”.

Intervention

5 papers study it3 findingsUpdated

See all 5 papers on COX-2 inhibitor

At a glance

The findings reach people, from one lab or study. 2 independent labs in 2 countries.

“and a 55% decrease among cyclooxygenase-2 (COX-2) inhibitor users (HR 0.45, 95% CI 0.26-0.78) during 6.3 years of average follow-up”
Non-steroidal Anti-inflammatory Drug Use and Risk of Age-Related Macular Degeneration in the California Teachers StudyDrugs & aging2021doi:10.1007/s40266-021-00885-z

1 of its findings points the other way.

Mice and humans: a single group. Cells and worms or flies: nothing yet.
  • 2 independent labs in 2 countries
  • 1 finding against
  • Funders: Brain & Behavior Research Foundation and others
  • Humans2
  • Animals2

What did studies of COX-2 inhibitor find?

1

Studies of COX-2 inhibitor measured one outcome, glucose uptake.

Glucose uptake

no changein mice1upin mice1

1 study
  1. COX-2 inhibitor showed no clear effect on glucose uptake in TgAPP-2576 mice.

    “COX-2 inhibition failed to stimulate glucose uptake in these mice”

    Animalsin TgAPP-2576 micehippocampus

    Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease

    Neuropharmacology

  2. COX-2 inhibitor increases glucose uptake in mice (acute hippocampal slices).

    “the selective inhibition of COX-2, rather than that of FAAH, MAGL or α,βDH6/12, also stimulates the uptake of glucose in hippocampal slices of middle-aged mice”

    Animalsacute hippocampal sliceshippocampus

    Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease

    Neuropharmacology

More on Glucose uptake

What is COX-2 inhibitor linked with?

1

Studies link COX-2 inhibitor with age-related macular degeneration.

Age-related macular degeneration

downin humans1HR 0.45

1 study
  1. COX-2 inhibitor is linked with a lower risk of age-related macular degeneration in humans (HR 0.45, 95% CI 0.26-0.78).

    “and a 55% decrease among cyclooxygenase-2 (COX-2) inhibitor users (HR 0.45, 95% CI 0.26-0.78) during 6.3 years of average follow-up”

    Humans6.3 yearsfemales

    Non-steroidal Anti-inflammatory Drug Use and Risk of Age-Related Macular Degeneration in the California Teachers Study

    Drugs & aging

More on Age-related macular degeneration

Latest